ChiCTR2300078120 版本V1.0 版本创建时间2023/11/29 10:50:29 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300078120 

最近更新日期:

Date of Last Refreshed on:

2023-11-29 10:47:44 

注册时间:

Date of Registration:

2023-11-29 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

艾司氯胺酮对控制性低中心静脉压肝部分切除术患者术后认知功能的影响——一项前瞻性队列研究

Public title:

Effect of Esketamine on Postoperative Cognitive Function in Patients Undergoing Partial Hepatic Resection with Controlled Low Central Venous Pressure: A Prospective Cohort Study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

艾司氯胺酮对控制性低中心静脉压肝部分切除术患者术后认知功能的影响——一项前瞻性队列研究

Scientific title:

Effect of Esketamine on Postoperative Cognitive Function in Patients Undergoing Partial Hepatic Resection with Controlled Low Central Venous Pressure: A Prospective Cohort Study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李进 

研究负责人:

李进 

Applicant:

Li Jin 

Study leader:

Li Jin 

申请注册联系人电话:

Applicant telephone:

+86 139 3111 3354

研究负责人电话:

Study leader's telephone:

+86 139 3111 3354

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

happyyky@163.com

研究负责人电子邮件:

Study leader's E-mail:

happyyky@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

河北省石家庄市新华区和平西路215号

研究负责人通讯地址:

河北省石家庄市新华区和平西路215号

Applicant address:

No. 215, Heping West Road, Xinhua District, Shijiazhuang City, Hebei Province

Study leader's address:

No. 215, Heping West Road, Xinhua District, Shijiazhuang City, Hebei Province

申请注册联系人邮政编码:

Applicant postcode:

050000

研究负责人邮政编码:

Study leader's postcode:

050000

申请人所在单位:

河北医科大学第二医院

Applicant's institution:

The Second Hospital of Hebei Medical University

研究负责人所在单位:

河北医科大学第二医院

Affiliation of the Leader:

The Second Hospital of Hebei Medical University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2023-R322

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

河北医科大学第二医院科研伦理委员会

Name of the ethic committee:

Research Ethics Committee of the second hospital of Hebei Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2023-06-30 00:00:00

伦理委员会联系人:

安文婷

Contact Name of the ethic committee:

An Wenting

伦理委员会联系地址:

河北省石家庄市新华区和平西路215号

Contact Address of the ethic committee:

No. 215, Heping West Road, Xinhua District, Shijiazhuang City, Hebei Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 311 6600 2811

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

河北医科大学第二医院

Primary sponsor:

The Second Hospital of Hebei Medical University

研究实施负责(组长)单位地址:

河北省石家庄市新华区和平西路215号

Primary sponsor's address:

No. 215, Heping West Road, Xinhua District, Shijiazhuang City, Hebei Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

河北省

市(区县):

石家庄市

Country:

China

Province:

Hebei Province

City:

Shijiazhuang City

单位(医院):

河北医科大学第二医院

具体地址:

河北省石家庄市新华区和平西路215号

Institution
hospital:

The Second Hospital of Hebei Medical University

Address:

No. 215, Heping West Road, Xinhua District, Shijiazhuang City, Hebei Province

经费或物资来源:

河北省卫生健康委员会

Source(s) of funding:

Health Commission of Hebei Provincial

Target disease:

Postoperative delirium

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

IV期临床试验 

Study phase:

4

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

(1)观察围术期应用艾司氯胺酮对控制性低中心静脉压肝部分切除术患者术后认知功能的影响。 (2)观察术中应用艾司氯胺酮对控制性低中心静脉压肝部分切除术患者术中血流动力学的影响。  

Objectives of Study:

(1) To observe the effect of perioperative application of esketamine on the postoperative cognitive function of patients undergoing controlled low central venous pressure partial hepatectomy. (2) To observe the effect of intraoperative application of esketamine on the intraoperative hemodynamics of patients undergoing controlled low central venous pressure partial hepatic resection.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

择期腹腔镜肝部分切除术;年龄≥18岁;ASA(美国麻醉医师协会)分级Ⅱ、Ⅲ。

Inclusion criteria

Scheduled laparoscopic partial hepatic resection; Age≥ 18; ASA (American Society of Anesthesiologists) II, III.

排除标准:

心功能3级以上、Child-Pugh C级以上、手术时间<2h或>6h、中枢神经系统疾病、视力或听力异常无法交流沟通者、术后转入ICU、参与其他研究项目者。

Exclusion criteria:

NYHA ≥ 3, Child-Pugh ≥C, operation time < 2h or > 6h, central nervous system diseases, vision or hearing abnormalities that cannot communicate, Admitted to ICU after surgery, participation in another research.

研究实施时间:

Study execute time:

From 2023-12-01 00:00:00 To 2024-11-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-12-01 00:00:00 To 2024-11-30 00:00:00  

干预措施:

Interventions:

组别:

艾司氯胺酮组

样本量:

45

Group:

Esketamine group

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

组别:

对照组

样本量:

45

Group:

Control group

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

河北省 

市(区县):

石家庄市 

Country:

China 

Province:

Hebei Province 

City:

Shijiazhuang City 

单位(医院):

河北医科大学第二医院 

单位级别:

三甲 

Institution
hospital:

The Second Hospital of Hebei Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术后谵妄

指标类型:

主要指标

Outcome:

Postoperative delirium

Type:

Primary indicator

测量时间点:

测量方法:

意识模糊评估法(CAM)

Measure time point of outcome:

Measure method:

confusion assessment method (CAM)

指标中文名:

术后认知功能

指标类型:

主要指标

Outcome:

postoperative cognitive function

Type:

Primary indicator

测量时间点:

测量方法:

蒙特利尔认知评估量表(MoCA)

Measure time point of outcome:

Measure method:

Montreal Cognitive Assessment(MoCA)

指标中文名:

全身炎性指标

指标类型:

主要指标

Outcome:

Systemic inflammation indicator

Type:

Primary indicator

测量时间点:

测量方法:

白介素-6

Measure time point of outcome:

Measure method:

IL-6

指标中文名:

血流动力学指标

指标类型:

主要指标

Outcome:

Hemodynamic indicators

Type:

Primary indicator

测量时间点:

测量方法:

收缩压、舒张压、平均动脉压、中心静脉压、脉搏变异度、心指数、体循环阻力指数

Measure time point of outcome:

Measure method:

SBP, DBP, MAP, CVP, SVV, CI, SVRI

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

NA

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2025年8月前在临床试验公共管理平台ResMan中共享,www.medresm.org

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Shared in ResMan by August 2025, www.medresm.org

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集前召开培训会,培训采集人员如何进行规范化操作。使用 ResMan 管理临床试验,试验完成后导出数据上传到 ResMan 共享。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

A meeting will be held to train relevant participants on how to collect the data and fill out the case record form. Clinical trials will be managed using ResMan.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-11-29 10:47:44